GlaxoSmithKline Surges On Report Activist Investor Takes ‘Significant’ Stake

GlaxoSmithKline (GSK) gained Thursday on a report activist investor Elliott Management has built a “significant” stake in the pharmaceutical giant. In early action, GSK stock gapped up.


According to the Financial Times, Elliott has gobbled up a large stake in GSK stock.

GlaxoSmithKline is working on spinning off its consumer health division into a joint venture with Pfizer (PFE). Meanwhile, its drug operations will operate as a standalone biopharma company.

On the stock market today, GSK stock surged 4.3% to 37.69. Shares touched their highest point since late January.

On a year-to-date basis, however, GSK stock was up 2.4% for the year, as of Thursday’s close. Shares have a poor Relative Strength Rating of 9 out of a best-possible 99. This means GSK stock outranks only 9% of stocks in terms of 12-month performance, according to IBD Digital.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


What Does The J&J Covid Vaccine Debacle Mean For Herd Immunity?

Moderna Stock Rises After New Covid Vaccine Tackles South Africa Variant

Follow Premarket And After-The-Open Action With IBD Experts

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Watch IBD’s Investing Strategies Show For Actionable Market Insights

Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button